X

Drug Profile

MTX 325

Alternative Names: MTX-325

Latest Information Update: 28 Mar 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator AbbVie; MISSION Therapeutics
Developer MISSION Therapeutics
Class Antiparkinsonians; Small molecules
Mechanism of Action Usp30 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Phase I Parkinson's disease
Preclinical Pelizaeus-Merzbacher disease

Most Recent Events

05 Dec 2023 MISSION Therapeutics plans a first-in-human phase I trial for Parkinson's disease in United Kingdom, in the first quarter of 2024
05 Dec 2023 MHRA approves CTA application for MTX 325 in Parkinson's disease
13 Nov 2023 Pharmacodynamics data rom preclinical studies in Parkinson's disease released by MISSION Therapeutics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com